News

Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

The month of May 2024 featured several notable studies in the field of dermatology, concerning topics such as a potential eczema flare vaccine, mobile versus in-person health, and skin cancer risk.

In an interview with HCPLive, Parthasarathy discussed the relationship between sleep disturbances and immune function.

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.

In an interview with HCPLive, DelRosso spoke about the 1-year plans of the "Count on Sleep" OSA project.

Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.

At SLEEP 2024, Revana told HCPLive her thoughts on the potential of pitolisant to address excessive daytime sleepiness in Prader-Willi syndrome compared to treating narcolepsy.

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.

Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.

These new, phase 3 data from Novartis suggest positive results from treatment with oral remibrutinib for patients with chronic spontaneous urticaria.

At 1 year, patients with treated with IL-23 switched or swapped biological treatment less frequently compared with IL-12/23, IL-17, and TNF-α inhibitors.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

Topline data from the pivotal Phase 3 trial show plozasiran met the primary endpoint of triglyceride-lowering in patients with the ultrarare genetic disease.

A quality improvement initiative exhibited a sustained increase in transcranial Doppler screening rates over an 8-year intervention period.

Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.

Analysis of the OASIS trial shows, on average, women post-menopause with vasomotor symptoms experience at least moderate rates of sleep disturbance.

A study presented as a late breaker at SLEEP 2024 found patients with COPD who have a greater mortality risk have a worse sleep quality.

A cohort analysis suggests upper airway collapsibility prevalence may correlate closely to race in patients with OSA.

New study data show patients with OSA may use a fixed CPAP device for a longer daily duration than those with an automatic option.

Presented at SLEEP 2024 as a late-breaker, a study found a positive relationship exists between suicide severity on any day and next-day suicide severity.

New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.

A study presented at SLEEP 2024 found medicinal cannabis shows promise for improving sleep onset latency, quality, and duration in children with ASD.

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

A study presented at SLEEP 2024 found melatonin increased sleep latency and overall sleep quality and decreased awakenings.

A late-breaking abstract from SLEEP 2024 shows the effect of mandibular devices on respiratory effort, and its overall impact on OSA.

An alternative device to CPAP shows clinical benefit and long-term patient adherence in new SLEEP 2024 trial data.